ClinicalTrials.gg
CompletedNCT01196546Updated Aug 1, 2017

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

A Phase 4 interventional study of vildagliptin/metformin in Type 2 Diabetes Mellitus, sponsored by Novartis. Completed at 8 sites in Thailand. Open to participants aged 18 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
60th of 118
161 · median 162
Started
2010
with 10 others
Phase 4
43 of 119
none open now
Registered
63rd of 119
by date
Lead sponsor
38 of 119
Novartis

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 60th largest by enrollment of the 118 interventional ones that give a count, is one of 11 that started in 2010, is one of 43 in phase 4, and was the 63rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • vildagliptin
  • metformin
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes mellitus patients who are treated with metformin monotherapy 1,000 mg daily for at least 3 months
  • The patient is required to have 6.5-11.0%
  • in the range of 22-48 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Severe or uncontrolled Type 2 diabetes mellitus (> 11.0%)
  • Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months
  • Congestive heart failure requiring pharmacologic treatment
  • Any of following within past 6 months: (1) myocardial infarction; (2) unstable angina (3) coronary artery bypass surgery or percutaneous coronary intervention
  • Liver disease such as cirrhosis or chronic active hepatitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Vildagliptin/metformin

    Drug: vildagliptin/metformin

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c reduction

    Time frame: 24 weeks after treatment

Secondary outcomes

  1. Proportion of patients who achieve target of HbA1c<6.5% at the end of study

    Time frame: 24 weeks after treatment

  2. To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles

    Time frame: 24 weeks after treatment

07

Study locations

8 sites
  • BMA Medical College and Vajira Hospital
    Bangkok, Thailand
  • King Chulalongkorn Memorial Hospital
    Bangkok, Thailand
  • Phamongkutklao Hospital
    Bangkok, Thailand
  • Police General Hospital
    Bangkok, Thailand
  • Siriraj Hospital
    Bangkok, Thailand
  • Khon Kaen Hospital
    Khon Kaen, Thailand
  • Fort Suranaree Hospital
    Nakhon Ratchasima, Thailand
  • Maharat Nakhon Ratchasima Hospital
    Nakhon Ratchasima, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2010
First posted
Sep 8, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01196546
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Sep 8, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Aug 1, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Metformin

Start the discussion